Department of Neurosurgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Dongfeng Dong Road, Guangzhou, 510000, China.
Department of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
J Neurooncol. 2023 Apr;162(2):327-335. doi: 10.1007/s11060-023-04293-8. Epub 2023 Mar 20.
Neurosurgical resection is a standard local treatment for lung cancer brain metastases (BMs). This study aims to investigate whether neurosurgical resection provides survival benefit in lung cancer BMs with poor KPS.
This multicenter retrospective study included 386 lung cancer BMs with pretreatment KPS ≤ 70 among a total of 1177 lung cancer BMs treated at three centers from August 2010 to July 2021. Data analysis was performed from July to September 2022. Inverse probability of treatment weighting (IPTW) and propensity scores matching (PSM) based on propensity scoring were used to minimize bias. The main outcome was overall survival (OS) after diagnosis of BMs. Risk factors of OS were estimated using Cox proportional hazards regression models. All Characteristics were included in the multivariate Cox regression.
386 patients with pretreatment KPS ≤ 70 were included (age mean [SD], 57.85 [10.36] years; KPS mean [SD], 60.91 [10.11]). Among them, 111 patients received neurosurgical resection, while 275 patients did not. Baseline characteristics were balanced between groups after IPTW or PSM. Neurosurgical resection was associated with significantly better prognosis in unadjusted multivariate COX analysis (hazard ratio [HR]: 0.68, 95% confidence interval [CI]: 0.51-0.91, P = 0.01), and PSM-adjusted multivariate COX analysis (HR: 0.61, 95%CI: 0.39-0.94, P = 0.03), IPTW-adjusted multivariate COX analysis (HR: 0.58, 95%CI: 0.40-0.84, P = 0.004). OS was significantly longer in neurosurgical resection group compared with non-surgical resection group according to unadjusted data (Median OS, surgery vs non-surgery, 14.7 vs 12.5 months, P = 0.01), PSM-adjusted data (median OS, 17.7 vs 12.3 months, P < 0.01) and IPTW-adjusted data (median OS, 17.7 vs 12.5 months, P < 0.01).
Neurosurgical resection was associated with improved survival in patients with lung cancer BMs with poor KPS, suggesting that poor KPS is not a contraindication for neurosurgical resection in these patients.
神经外科切除术是治疗肺癌脑转移(BMs)的标准局部治疗方法。本研究旨在探讨在 KPS 较差的肺癌 BMs 患者中,神经外科切除术是否能带来生存获益。
本多中心回顾性研究纳入了三家中心 2010 年 8 月至 2021 年 7 月间共 1177 例肺癌 BMs 患者中,术前 KPS≤70 的 386 例肺癌 BMs。数据分析于 2022 年 7 月至 9 月进行。采用倾向评分匹配(PSM)和基于倾向评分的逆概率治疗加权(IPTW)以最小化偏倚。主要观察终点为 BMs 确诊后的总生存(OS)。采用 Cox 比例风险回归模型评估 OS 的风险因素。所有特征均纳入多变量 Cox 回归。
共纳入 386 例术前 KPS≤70 的患者(年龄均值[标准差]为 57.85[10.36]岁;KPS 均值[标准差]为 60.91[10.11])。其中 111 例患者接受了神经外科切除术,275 例患者未接受。经 IPTW 或 PSM 后,两组间的基线特征得到了平衡。在未调整的多变量 COX 分析中,神经外科切除术与显著更好的预后相关(风险比[HR]:0.68,95%置信区间[CI]:0.51-0.91,P=0.01),在 PSM 调整的多变量 COX 分析中(HR:0.61,95%CI:0.39-0.94,P=0.03),以及 IPTW 调整的多变量 COX 分析中(HR:0.58,95%CI:0.40-0.84,P=0.004)。根据未调整的数据(中位 OS,手术组 vs 非手术组,14.7 个月 vs 12.5 个月,P=0.01),PSM 调整的数据(中位 OS,17.7 个月 vs 12.3 个月,P<0.01)和 IPTW 调整的数据(中位 OS,17.7 个月 vs 12.5 个月,P<0.01),神经外科切除术组的 OS 明显长于非手术切除术组。
在 KPS 较差的肺癌 BMs 患者中,神经外科切除术与生存改善相关,提示在这些患者中,KPS 差并不是神经外科切除术的禁忌证。